Lilly Entered into a Research and Collaboration Agreement with Entos to Develop Nucleic Acid-Based Therapies in Multiple Neurologic Indications
Shots:
- Entos to receive a $50M up front including an equity investment & is also eligible to receive ~$400M upon the achievement of development and commercial milestone for each program along with royalties
- The collaboration will combine Entos' Fusogenix nucleic acid delivery technology with Lilly's therapeutic to deliver nucleic acid therapies to the nervous system
- Entos will be responsible for the generation, development, and optimization of PLVs using its Fusogenix platform technology. Lilly will be responsible for selecting PLVs for clinical development and commercialization
Ref: Lilly | Image: Bilaterals
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com